Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

NCT01272232 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide on body weight in adults who are overweight or obese and have type 2 diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 846 people

Who can join Ages 18+ · all sexes

Timeline Started 2011-06 · est. completion 2013-01

Where 161 sites · France, Germany, India, Israel, Italy, Puerto Rico, South Africa, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT01272232 ↗

Description as written by the study sponsor.

This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of this trial is to investigate the potential of liraglutide to induce and maintain weight loss in overweight or obese subjects with type 2 diabetes. Treatment will be added onto subject's pre-trial background diabetes treatment of either diet and exercise only or single compound oral antidiabetic drug (OAD) treatment (metformin, sulphonylurea \[SU\] or glitazone) or combination OAD treatment (metformin, sulphonylurea or glitazone). The duration of the trial will be 56 weeks followed by a 12 week observational follow-up period.

Treatments tested

liraglutide Drug

Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
liraglutide Drug

Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
placebo Drug

Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.

Main thing measured	Change (%) From Baseline in Body Weight (Fasting)
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01272232 ↗